Pardes reports interim data from Phase I trial of oral Covid-19 antiviral

Pardes Biosciences has reported interim results from the Phase I trial of its oral antiviral drug, PBI-0451, in healthy adult subjects.

Related Keywords

New Zealand ,Pardes Biosciences ,Drug Administration ,Parde Investigational New Drug ,Preference Management Solution ,Key Challenges ,Global Clinical Trial ,